INM
InMed Pharmaceuticals Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 3 ▼ InMed Pharmaceuticals is conducting an at-the-market offering of up…
- Apr 27 ▼ InMed Pharmaceuticals amended preferred investment options (warrants…
- May 19 ▲ InMed Pharmaceuticals (INM) entered into a definitive agreement to a…
- May 19 to May 21 ▲ 3 days of insider buys: $866.7K by 2 insiders, avg $1.55
- May 29 to Jun 8 ▲ 7 days of insider buys: $246.4K by 1 insider, avg $1.55
- Jun 30 to Jul 2 ▲ 3 days of insider buys: $10.1K by 1 insider, avg $1.55
- Jul 14 to Jul 16 ▲ 3 days of insider buys: $33.4K by 2 insiders, avg $1.55
- Sep 14 to Sep 16 ▲ 3 days of insider buys: $118.1K by 1 insider, avg $1.30
- Oct 1 to Oct 23 ▲ 12 days of insider buys: $85.7K by 1 insider, avg $1.33
- Oct 15 HSR Early Termination: InMed Pharmaceuticals Inc; Mentari…
- Oct 30 ▼ Short interest jumps 855.8% to 63.4K
- Nov 5 Trading halt: Trading Halt: INM · T1 (News Pending)
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $1.4M. No open-market sales.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 0 trimmed or exited.
- Short sellersBUILDING
Short interest +855.8% to 63.4K shares. 1.0 days to cover, ≈11.5% of shares.
- TrendUPTREND
39% above its 50-day average. New closing high $19.87 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value | |
|---|---|---|---|
| CITADEL ADVISORS LLC | TRIM | $40.4K | |
| UBS Group AG | DOUBLED | $5.2K | |
| Federation des caisses Desjardins du Quebec | DOUBLED | $4.00 | |
| UBS Group AG | ADD | $25.2K | |
| UBS Group AG | TRIM | $12.6K | |
| CITADEL ADVISORS LLC | DOUBLED | $13.3K | |
| HRT FINANCIAL LP | DOUBLED | $8.0K | |
| 🔒 Fresh data, subscribers only | ADD | ||
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ADAR1 Capital Management, LLC 10%+ Owner Oct 23, 2026 | BUY | $5.28 |
ADAR1 Capital Management, LLC 10%+ Owner Oct 19, 2026 | BUY | $1.4K |
ADAR1 Capital Management, LLC 10%+ Owner Oct 16, 2026 | BUY | $1.32 |
ADAR1 Capital Management, LLC 10%+ Owner Oct 15, 2026 | BUY | $1.3K |
ADAR1 Capital Management, LLC 10%+ Owner Oct 14, 2026 | BUY | $10.7K |
ADAR1 Capital Management, LLC 10%+ Owner Oct 13, 2026 | BUY | $750.12 |
ADAR1 Capital Management, LLC 10%+ Owner Oct 8, 2026 | BUY | $3.0K |
ADAR1 Capital Management, LLC 10%+ Owner Oct 7, 2026 | BUY | $4.1K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026| Nov 5, 2026 | Volatility Pause | Resumed |
| Nov 4, 2026 | Resumption Scheduled | Resumed |
SecBot reports
22 filings · 3 bullish · 9 bearish · 1 mixed · 9 neutral- NEUTRAL 8-KNov 9, 2026
Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari…
Monitor Phase 1 data for MT-001 expected mid-2027 and regulatory filing for MT-002 in Q1 2027. The $490M financing provides a multi-year runway, reducing near-term dilution risk.
- NEUTRAL 8-KNov 5, 2026
InMed Pharmaceuticals (INM) reported shareholder approval of all proposals at its annual meeting…
The merger with Mentari Therapeutics remains subject to closing conditions; monitor for a subsequent 8-K announcing the merger's completion or any delays. The CVR terms and potential payouts are not…
- NEUTRAL 8-KNov 5, 2026
InMed Pharmaceuticals Inc. held its annual general and special meeting on November 4, 2026, where…
Monitor for the closing of the merger with Mentari Therapeutics, which remains subject to conditions. The creation of Series A Preferred Shares with conversion rights and board representation rights…
- BEARISH 8-KNov 3, 2026
InMed Pharmaceuticals reported Q1 FY2027 results with a net loss of $2.33M, cash burn reducing…
The shareholder vote on the Mentari merger is the critical near-term catalyst. If approved, the $490M private placement could resolve the cash and Nasdaq compliance issues. If the merger fails…
All INM filing & press-release reports (22)
- 8-K reportNov 9, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 3, 2026
- 425 reportNov 2, 2026
- 425 reportOct 26, 2026
- SC 13G/A reportOct 7, 2026
- EFFECT reportOct 2, 2026
- 8-K reportSep 18, 2026
- 425 reportSep 9, 2026
- 8-K reportJul 10, 2026
- S-4 reportJul 2, 2026
- CLUSTER reportJun 10, 2026
- 8-K reportJun 10, 2026
- 425 reportMay 19, 2026
- 8-K reportMay 19, 2026
- 8-K reportMay 19, 2026
- 8-K reportApr 27, 2026
- 8-K reportApr 3, 2026
- 424B5 reportApr 3, 2026
- EFFECT reportMar 31, 2026
- S-3 reportMar 20, 2026